Activated Clotting Time during Percutaneous Coronary Intervention

Circulation: Cardiovascular Interventions

Volumn 8, Issue 4, 2015, Pages

  Ndrepepa, Gjin ^a   Kastrati, Adnan ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

coronary balloon angioplasty; Editorials; hemorrhage; heparin; thrombosis

Indexed keywords

CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; TICLOPIDINE; TRANQUILIZER;

ANTICOAGULANT THERAPY; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CORONARY STENT; EDITORIAL; HEMATOLOGY EQUIPMENT; HEPARINIZATION; HUMAN; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); FEMALE; MALE; MYOCARDIAL INFARCTION; POSTOPERATIVE HEMORRHAGE; PROCEDURES; THROMBOSIS;

FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; THROMBOSIS; WHOLE BLOOD COAGULATION TIME;

EID: 84937440478     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.115.002576     Document Type: Editorial

References (24)

1. Murray DW, Jaques LB, Perrett TS, Best CH. Heparin and vascular occlusion. Can Med Assoc J. 1936;35:621-622.
2. Crafoord C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis. Acta Chir Scand Suppl. 1936;79:407-413.
3. Hattersley PG. Activated coagulation time of whole blood. JAMA. 1966;196:436-440.
4. Bates SM, Weitz JI. Coagulation assays. Circulation. 2005;112:e53-e60. Doi: 10. 1161/CIRCULATIONAHA. 104. 478222.
5. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevationmyocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-e425. Doi: 10. 1161/CIR. 0b013e3182742cf6.
6. Popma JJ, Weitz J, Bittl JA, Ohman EM, Kuntz RE, Lansky AJ, King SB III. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest. 1998;114(5 suppl):728S-741S.
7. McGarry TF Jr, Gottlieb RS, Morganroth J, Zelenkofske SL, Kasparian H, Duca PR, Lester RM, Kreulen TH. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1992;123:1445-1451.
8. Ferguson JJ, Barasch E, Wilson JM, Strony J, Wolfe MW, Schweiger MJ, Leya F, Bonan R, Isner JM, Roubin GS, Cannon AD, Cleman M, Cabin HS, Adelman B, Bittl JA. The relation of clinical outcome to dissection and thrombus formation during coronary angioplasty. Heparin Registry Investigators. J Invasive Cardiol. 1995;7:2-10.
9. Narins CR, Hillegass WB Jr, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 1996;93:667-671.
10. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103:961-966.
11. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation. 2004;110:994-998. Doi: 10. 1161/01. CIR. 0000139868. 53594. 24.
12. Tolleson TR, O'Shea JC, Bittl JA, Hillegass WB, Williams KA, Levine G, Harrington RA, Tcheng JE. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. 2003;41:386-393.
13. Ducrocq G, Jolly S, Mehta SR, Rao SV, Patel T, Moreno R, Gao P, Steg PG. Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-elevation myocardial infarction: insights from the FUTURA/OASIS-8 trial. Circ Cardiovasc Interv. 2015;8:e002044. Doi: 10. 1161/CIRCINTERVENTIONS. 114. 002044.
14. Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, Lopez-Sendon JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Joyner C, Pogue J, Yusuf S. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux. The FUTURA/OASIS-8 randomized trial. JAMA. 2010;304:1339-1349.
15. Bertrand OF, Rodés-Cabau J, Rinfret S, Larose E, Bagur R, Proulx G, Gleeton O, Costerousse O, De Larochellière R, Roy L. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy. Am J Cardiol. 2009;104:1235-1240. Doi: 10. 1016/j. Amjcard. 2009. 06. 036.
16. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-2619.
17. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519-1530. Doi: 10. 1001/jama. 295. 13. joc60038.
18. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574. Doi: 10. 1056/ NEJM199105303242206.
19. Montalescot G, Cohen M, Salette G, Desmet WJ, Macaya C, Aylward PE, Steg PG, White HD, Gallo R, Steinhubl SR; STEEPLE Investigators. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur Heart J. 2008;29:462-471. Doi: 10. 1093/eurheartj/ehn008.
20. Björk I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem. 1982;48:161-182.
21. Topol EJ. Caveats about elective coronary stenting. N Engl J Med. 1994;331:539-541.
22. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251-256.
23. Barradas MA, Mikhailidis DP, Epemolu O, Jeremy JY, Fonseca V, Dandona P. Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222). Br J Haematol. 1987;67:451-457.
24. Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ. Heparin promotes platelet responsiveness by potentiating IIb3-mediated outside-in signaling. Blood. 2011;117:4946-4952. Doi: 10. 1182/ blood-2010-09-307751.